论文部分内容阅读
中国加入WTO,机遇随之而来。由于中国的零售药品市场是一片待开发的处女地并且位于低端,医药产业本身的存量资金和社会游资开始大规模的涌入。销售终端市场的跑马圈地烽烟骤起。 群雄逐鹿 随着我国医保制度和全面实施的药品分类管理制度的进一步完善,药品零售市场还将进一步扩大,专家预计在未来五年内将以年均15％的速度增长,到2005年可望达到600亿元,2020年我国将成为全球最大的OTC销售市场之一。 国家药品监督管理局今年1月底表示,目前我国医药零售企业仅12万家,今后零售药店可以发展到30万家,缺口18
China’s accession to WTO, followed by opportunities. As China’s retail pharmaceutical market is a virgin land yet to be developed and is located at the low end, a large-scale influx of medical funds and social hot money from the pharmaceutical industry itself began. Stallion sales end of the market bubble stormed. Fighting the Crowd As China’s health insurance system and the full implementation of the drug classification management system to further improve the pharmaceutical retail market will be further expanded, the experts are expected to grow at an average annual rate of 15% in the next five years to 600 in 2005 is expected to reach 600 In 2020, China will become one of the largest OTC sales markets in the world. State Drug Administration at the end of January this year, said that at present, China’s pharmaceutical retailers only 120,000, the future retail pharmacies can grow to 300,000, the gap 18